Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

janssen pharmaceutical k.k. - selexipag - pale reddish brown tablet, diameter: 7.1 mm, thickness: 3.4 mm

Japani - Kiingereza - すりの適正使用協議会 RAD-AR Council, Japan

nippon shinyaku co., ltd. - selexipag - pale reddish brown tablet, diameter: 7.1 mm, thickness: 3.4 mm

Saudi - Kiingereza - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - selexipag - film-coated tablet - 800 µg,

Saudi - Kiingereza - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - selexipag - film-coated tablet - 400 µg,

Marekani - Kiingereza - NLM (National Library of Medicine)

eurofins amatsigroup sas - selexipag (unii: 5exc0e384l) (selexipag - unii:5exc0e384l) -

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg;  ; bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg - film coated tablet - 62.5 mg - active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 64.541mg equivalent to bosentan anhydrous 62.5 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - tolterodine tartare - prolonged release capsules - 2 milligram - drugs for urinary frequency and incontinence

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

ltt pharma limited - tolterodine tartrate - prolonged release capsules - 4 milligram

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tolterodine l-tartrate - prolonged-release capsule - 4 milligram(s) - drugs for urinary frequency and incontinence; tolterodine